From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL
Standard therapy options are limited for patients with refractory chronic lymphocytic leukemia, with or without lymphadenopathy, and the results are generally poor. Ofatumumab (Arzerra), a novel human CD20 monoclonal antibody, could be the answer for improving outcomes in this patient population. Lead investigator William G. Wierda, MD, PhD, will share the final analysis of the results from this international study at ASH 2010.
To the Editor: We read with interest the article by Lopez et al.1 They compared the effects of AMG 641 with calcitriol (CT) or paricalcitol (PC) alone, and the combination of the calcimimetic with either CT or PC. We have really found the paper interesting, but would like to raise some points of discussion.